Adjuvant Aromatase Inhibitor Options in Overweight and Obese Postmenopausal Women with Breast Cancer

Breast Journal

Volumn 19, Issue 5, 2013, Pages 552-554

  Chlebowski, Rowan T ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; GOSERELIN; HORMONE RECEPTOR; LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; BODY MASS; BREAST CANCER; CANCER SURVIVAL; CLINICAL PRACTICE; FOLLOW UP; INTENTION TO TREAT ANALYSIS; LETTER; OBESITY; OVERALL SURVIVAL; POSTMENOPAUSE; QUALITY OF LIFE; TREATMENT OUTCOME;

AROMATASE INHIBITORS; BODY MASS INDEX; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NITRILES; OBESITY; OVERWEIGHT; POSTMENOPAUSE; TRIAZOLES;

EID: 84884901459     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12167     Document Type: Letter

References (26)

1. Ewertz M, Gray KP, Regan MM, et al,. Obesity and risk of recurrence or death following adjuvant endocrine therapy with letrozole or tamoxifen in the BIG 1-98 trial. J Clin Oncol 2012; 30: 3967-3975.
2. Sestak I, Distler W, Forbes JF, et al,. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analyses from the ATAC trial. J Clin Oncol 2010; 28: 3411-3415.
3. Gnant M, Pfeiler G, Stoger H, et al,. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. Br J Cancer 2013; doi: 10.1038/bjc.2013.367 [Epub ahead of print].
4. Pfeiler G, Konigsberg R, Fesl C, et al,. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011; 28: 3405-3407.
5. Wang Y, Beydoun MA, Liang L, Caballero B, Kumanyika SK,. Will all Americans become overweight or obese? Estimating the progression and cost of the US obesity epidemic. Obesity 2008; 16: 2323-2330.
6. Shields M, Carroll MD, Ogden CL,. Adult obesity prevalence in Canada and the United States. NCHS Data Brief 2011; 56: 1-8.
7. Chlebowski RT, Ligibel JA,. Lifestyle issues in breast cancer survivors. In:, Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast, 4th edn. Philadelphia: Lippincott Williams & Wikins, 2010: 676-682.
8. Protani M, Coory M, Martin JH, et al,. Effect of obesity on survival of women with breast cancer: systematic review and meta-analyses. Breast Cancer Res Treat 2010; 123: 627-35.
9. Regan MM, Neven P, Giobbie-Hurder A, et al,. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomized clinical trial at 8.1 years follow-up. Lancet Oncol 2011; 12: 1101-08.
10. Cuzick J, Sestak I, Baum M, et al,. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analyses of the ATAC trial. Lancet Oncol 2010; 11: 1135-41.
11. O'Shaughnessy J,. A decade of letrozole. FACE. Breast Cancer Res Treat 2007; 105: 67-74.
12. Ewertz M, Jensen MB, Gunnarsodottir KA, et al,. Effect of obesity on prognosis after early stage breast cancer. J Clin Oncol 2011; 29: 25-31.
13. Dixon JM, Renshaw L, Young O, et al,. Letrozole suppresses plasma estradiol estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 2008; 26: 1671-6.
14. Folkerd EJ, Dixon JM, Renshaw L, A'Hern RP, Dowsett M,. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass Index in patients with breast cancer. J Clin Oncol 2012; 30: 2977-2980.
15. Geisler J, Helle H, Ekse D, et al,. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res 2008; 14: 6330-5.
16. Azim AA, Costantini-Ferrando M, Lostritto K, Oktay K,. Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab 2007; 92: 2197-200.
17. Ligibel JA, Winer EP,. Aromatase inhibition in obese women: how much is enough? J Clin Oncol 2012; 30: 2940-2841.
18. Burstein HJ, Prestrud AA, Seidenfeld J, et al,. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3787-90.
19. Goss PE, Ingle JN, Chapman JAW, et al,. Final analysis of NCIC CTG MA27: a randomized phase III trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive primary breast cancer. 33rd Annual San Antonio Breast Cancer Symposium. Abstract S1-1. Presented December 9, 2010.
20. Ellis MJ, Buzdar A, Unzeitig GW, et al,. ACOSOG Z1031: a randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer. J Clin Oncol 2010; 28: 18S.
21. Cuppone F, Sestak I, Verma S, et al,. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta Analysis of randomized trials Cancer 2008; 112: 260-7.
22. Amir E, Seruga B, Niraula S, et al,. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systemic review and meta- analysis. J Natl Cancer Inst 2011; 103: 1299-1309.
23. Visvanathan K, Chlebowski RT, Hurley P, et al,. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009; 27: 3235-58.
24. Younus K, Kissner M, Reich L, et al,. Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective. Drug Sat 2011; 34: 1125-1149.
25. Chlebowski RT, Cuzick J, Amakye D, et al,. Clinical issues regarding aromatase inhibitor use in breast cancer adjuvant therapy. The Breast 2009; 18 (suppl 2): S1-S11.
26. Geisler J,. Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole-of clinical importance? Br J Cancer 2011; 104: 1059-1066.